Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Climb 4.8% – Time to Buy?

Posted by Brenda Bartman on Oct 7th, 2026

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) were up 4.8% on Wednesday. The stock traded as high as $82.73 and last traded at $83.0680. Approximately 599,622 shares changed hands during trading, a decline of 30% from the average daily volume of 851,888 shares. The stock had previously closed at $79.25.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MIRM. Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday, August 6th. Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Royal Bank Of Canada cut their price objective on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Citizens Jmp restated a “market outperform” rating and set a $137.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. Finally, TD Cowen lowered their target price on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $142.56.

View Our Latest Analysis on Mirum Pharmaceuticals

Mirum Pharmaceuticals Price Performance

The stock has a market capitalization of $5.37 billion, a price-to-earnings ratio of -5.69 and a beta of 0.61. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The business’s 50 day simple moving average is $96.63 and its 200-day simple moving average is $101.11.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The firm had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. Mirum Pharmaceuticals’s quarterly revenue was up 37.9% compared to the same quarter last year. On average, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total value of $2,960,400.00. Following the transaction, the chief executive officer owned 194,440 shares in the company, valued at approximately $19,187,339.20. This trade represents a 13.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total value of $4,000,000.00. Following the transaction, the senior vice president directly owned 1,274 shares of the company’s stock, valued at $127,400. This trade represents a 96.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 98,499 shares of company stock worth $9,797,834 over the last three months. Corporate insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jupiter Topco LLC acquired a new position in Mirum Pharmaceuticals during the 2nd quarter worth approximately $691,672,000. Janus Henderson Group PLC grew its stake in shares of Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after buying an additional 880,505 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Mirum Pharmaceuticals during the second quarter worth $513,945,000. ABS Investment Management LLC acquired a new position in shares of Mirum Pharmaceuticals during the second quarter worth $245,847,000. Finally, William Blair Investment Management LLC bought a new position in shares of Mirum Pharmaceuticals in the 2nd quarter valued at $164,453,000.

Mirum Pharmaceuticals Company Profile

(Get Free Report)

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.